{"id":55542,"date":"2024-02-07T05:29:25","date_gmt":"2024-02-07T05:29:25","guid":{"rendered":"https:\/\/medsname.com\/arzodel\/"},"modified":"2026-04-30T10:24:47","modified_gmt":"2026-04-30T10:24:47","slug":"arzodel","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/arzodel\/","title":{"rendered":"Arzodel"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 Rychl\u00e1 odpov\u011b\u010f<\/h3>\n

Arzodel (Aripiprazole 5 \/ 10 \/ 15 mg) is an atypical antipsychotic with a unique D2 partial-agonist mechanism. Used for schizophrenia, bipolar mania and maintenance, MDD adjunct, and irritability in autism. Most metabolically clean of the atypicals \u2014 minimal weight gain, minimal sedation.<\/p>\n<\/div>\n

\nCo z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdrobce certifikovan\u00fd WHO-GMP \u00b7 Diskr\u00e9tn\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 doprava \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a>\n<\/div>\n

\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n

Pro\u010d objedn\u00e1vat z MedsBase<\/h3>\n

Arzodel at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a> \u2014 20pracovn\u00edchdenn\u00ed lh\u016fta pro doru\u010den\u00ed, nebo v\u00e1m z\u00e1silku zdarma p\u0159epo\u0161leme \u2014 a oprav\u0148uje v\u00e1s k \u00fa\u010dasti v na\u0161em v\u011brnostn\u00edm programu<\/a>. Dod\u00e1v\u00e1me do v\u011bt\u0161iny zem\u00ed po cel\u00e9m sv\u011bt\u011b.<\/p>\n

What Arzodel is and how it works<\/h2>\n

Arzodel is an aripiprazole tablet supplied by Torrent. Available strengths: 5 \/ 10 \/ 15 mg<\/strong>. Aripiprazole is mechanistically distinct from other atypical antipsychotics: it acts as a partial agonist<\/strong> at dopamine D2 and serotonin 5-HT1A receptors and a full antagonist at 5-HT2A receptors. The partial-agonist profile means it functions as an antagonist where dopamine activity is high (treating positive symptoms in schizophrenia) and as a weak agonist where dopamine activity is low (preserving cognition, lowering risk of motor side effects and hyperprolactinaemia).<\/p>\n

Indikace a d\u00e1vkov\u00e1n\u00ed<\/h2>\n\n\n\n\n\n\n\n\n\n\n
Indikace<\/th>\nPo\u010d\u00e1te\u010dn\u00ed d\u00e1vka<\/th>\nC\u00edlov\u00e1 d\u00e1vka<\/th>\nMaxim\u00e1ln\u00ed d\u00e1vka<\/th>\n<\/tr>\n<\/thead>\n
Schizophrenia (adult)<\/td>\n10\u201315 mg OD<\/td>\n10\u201330 mg OD<\/td>\n30 mg<\/td>\n<\/tr>\n
Schizophrenia (adolescent \u2265 13 y)<\/td>\n2 mg OD \u00d7 2 d \u2192 5 mg \u00d7 2 d \u2192 10 mg<\/td>\n10 mg OD<\/td>\n30 mg<\/td>\n<\/tr>\n
Bipolar mania (adult)<\/td>\n15 mg OD<\/td>\n15\u201330 mg OD<\/td>\n30 mg<\/td>\n<\/tr>\n
MDD adjunct (with antidepressant)<\/td>\n2\u20135 mg OD<\/td>\n5\u201310 mg OD<\/td>\n15 mg<\/td>\n<\/tr>\n
Autism irritability (\u2265 6 y)<\/td>\n2 mg OD<\/td>\n5\u201310 mg OD (weight-based)<\/td>\n15 mg<\/td>\n<\/tr>\n
Tourette syndrome (\u2265 6 y)<\/td>\n2 mg OD<\/td>\n5\u201320 mg OD<\/td>\n20 mg<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Single daily dose, with or without food. Titrate slowly in patients sensitive to akathisia.<\/p>\n

D\u016fle\u017eit\u00e9 bezpe\u010dnostn\u00ed aspekty<\/h2>\n
\nFDA black-box \u2014 dementia-related psychosis<\/strong><\/p>\n

All atypical antipsychotics carry an FDA black-box warning for increased mortality (mostly cardiovascular and infectious) when used to treat behavioural disturbance in older adults with dementia. Atypicals are not approved for dementia-related psychosis or agitation<\/strong>. Use in this population is off-label, last-resort, time-limited, and requires explicit risk-benefit conversation.<\/p>\n<\/div>\n

\nAkathisia is the dominant side effect<\/strong><\/p>\n

Aripiprazole produces less weight gain, less sedation, and less prolactin elevation than other atypicals \u2014 but more akathisia<\/strong> (an inner sense of restlessness, often described as “needing to move”, “skin crawling”, or “can’t sit still”). Akathisia is the most common cause of aripiprazole discontinuation. Manage with dose reduction, propranolol 20\u201380 mg\/day, or switch.<\/p>\n<\/div>\n

\nImpulse-control disorders (rare)<\/strong><\/p>\n

Pathological gambling, hypersexuality, compulsive shopping, and binge eating have been reported on aripiprazole \u2014 caused by the partial D2\/D3 agonism. Stops on discontinuation. Ask explicitly at follow-up.<\/p>\n<\/div>\n

\nSuicidality black-box (under-25 in MDD adjunct use)<\/strong><\/p>\n

When used as an antidepressant adjunct, the under-25 suicidality warning applies.<\/p>\n<\/div>\n

\u010cast\u00e9 ne\u017e\u00e1douc\u00ed \u00fa\u010dinky<\/h2>\n